Takara Bio Inc. (FRA:TF2)

Market Cap	507.06M
Revenue (ttm)	253.84M
Net Income (ttm)	-36.76M
Shares Out	n/a
EPS (ttm)	-0.31
PE Ratio	n/a
Forward PE	n/a
Dividend	0.10 (2.69%)
Ex-Dividend Date	Mar 28, 2025

Volume	n/a
Average Volume	83
Open	4.020
Previous Close	3.980
Day's Range	3.880 - 4.020
52-Week Range	3.880 - 6.450
Beta	n/a
RSI	35.37
Earnings Date	Feb 12, 2026

About Takara Bio

Takara Bio Inc., together with its subsidiaries, engages in the businesses of reagents, equipment, contract services, and genetic medicine in Japan, China, the rest of Asia, the United States, Europe, and internationally. The company sells reagents and instruments, including reagents needed for genetic and cellular research, PCR instruments, cellular analysis devices, and in vitro diagnostics for COVID-19 testing. It also provides contract services related to regenerative medicine products and contract services related to gene analysis and test...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2002
• Employees: 1,779
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: TF2

Financial Performance

In 2024, Takara Bio's revenue was 45.04 billion, an increase of 3.53% compared to the previous year's 43.51 billion. Earnings were 1.04 billion, a decrease of -29.66%.

Financial numbers in JPY